Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Active not recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1Lymphoid 1Gastrointestinal 1Dermatologic 1CNS 1

Conditions

Neoplasms 16Carcinoma, Non-Small-Cell Lung 10Ovarian Neoplasms 6Endometrial Neoplasms 4Squamous Cell Carcinoma of Head and Neck 3Melanoma 3Head and Neck Neoplasms 3Colorectal Neoplasms 3Stomach Neoplasms 2Rectal Neoplasms 2Osteosarcoma 2Neoplasm Metastasis 2Multiple Myeloma 2Lung Neoplasms 2Colonic Neoplasms 2Rhabdomyosarcoma 1Recurrence 1Non-Squamous Non-Small Cell Lung Cancer (NSCLC) 1Neuroblastoma 1Neoplasms by Site 1Hodgkin Disease 1Hepatoblastoma 1Glioblastoma 1Gastrointestinal Neoplasms 1Fibrolamellar hepatocellular carcinoma 1Fallopian Tube Neoplasms 1Ependymoma 1Digestive System Neoplasms 1Diffuse Intrinsic Pontine Glioma 1Carcinoma, Renal Cell 1

Interventions

Temozolomide 5Irinotecan 3Cyclophosphamide 3Topotecan 2palbociclib 1olutasidenib 1nimotuzumab 1dostarlimab 1dipinacoline glutamate 1dinutuximab 1cemiplimab 1abemaciclib 1TIC10 compound 1Re-Irradiation 1OKN 007 1Maintenance 1Injections 1Granulocyte-Macrophage Colony-Stimulating Factor 1Etoposide 1Drug Tolerance 1Congresses as Topic 1CLR1404 13-(5-fluorobenzofuran-3-yl)-4-(5-methyl-5H-(1,3)dioxolo(4,5-f)indol-7-yl)-pyrrole-2,5-dione 11-methyltryptophan 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
INDUSTRY × Diffuse Intrinsic Pontine Glioma × dostarlimab × Clear all
NCT06521567 2025-11-12

A Study of Cobolimab Plus Dostarlimab in Pediatric and Young Adult Participants With Cancer

GlaxoSmithKline

Phase 1/2 Active not recruiting
83 enrolled
CNSDermatologicGastrointestinalLymphoidSarcoma

Fibrolamellar hepatocellular carcinoma, Diffuse Intrinsic Pontine Glioma, Ependymoma, Glioblastoma, Carcinoma, Hepatocellular, Hodgkin Disease, Melanoma, Rhabdomyosarcoma, Osteosarcoma, Hepatoblastoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡